Carl Dambkowski, Director of Oruka Therapeutics (NASDAQ: ORKA), sold 105,000 shares of common stock on May 21, 2026, for approximately $6.19 million, marking a significant reduction of 58.74% in his direct holdings. This transaction was executed through the exercise and immediate sale of options, leaving Dambkowski with 73,743 shares directly, alongside a substantial number of remaining stock options.

This sale comes at a time when Oruka Therapeutics is experiencing notable momentum, with its stock having surged about 407% over the past year, largely driven by positive clinical trial results for its lead candidate, ORKA-001. Investors are keenly watching for further updates, particularly the anticipated long-term results later in 2026 and phase 2 trial results for ORKA-002 in 2027. Dambkowski’s substantial remaining equity and options suggest he still maintains a vested interest in the company’s future.

For market professionals, this transaction raises questions about insider sentiment and potential implications for stock performance. While Dambkowski’s sale could be interpreted as a reduction in confidence, his retained options indicate ongoing alignment with shareholder interests. Investors should weigh this alongside Oruka’s promising drug pipeline as they consider their positions.

Source: nasdaq.com